News
Merck & Co., Inc. (NYSE:MRK) is one of the 12 stocks that will make you rich in 10 years. On June 23, the company shared encouraging results from its Phase 3 HYPERION trial.
Merck & Co., Inc. (NYSE:MRK) is a leading pharmaceutical company, best known for its strong presence in oncology, ...
Merck's heavy reliance on Keytruda continues to grow, with the drug nearing 50% of total sales and limited growth from other ...
A newly configured federal vaccine panel's June 25 action is expected to improve options to protect infants from potentially ...
2d
Zacks Investment Research on MSNMerck (MRK) Stock Falls Amid Market Uptick: What Investors Need to KnowIn the latest trading session, Merck (MRK) closed at $78.83, marking a -1.05% move from the previous day. This change lagged the S&P 500's 0.8% gain on the day. Meanwhile, the Dow gained 0.94%, and ...
The vote offers a sigh of relief to doctors and public health experts worried about vaccine skepticism creeping into policymaking.
Debt-to-equity ratios vary by company and industry, but in general, a ratio of 1.0 or less is considered rather safe. One of ...
For high-risk patients with type 2 diabetes, oral semaglutide reduced risk for major cardiovascular and ischemic limb-related ...
A CDC advisory panel on Thursday voted 5-2 to recommend the use of a new preventative RSV therapy in babies, Merck’s ...
The votes in favor of Merck’s shot are a sigh of relief after Kennedy gutted the panel and tapped replacements, some of whom ...
CDC advisers recommend Merck's Enflonsia to protect babies from RSV, addressing the leading cause of infant hospitalization ...
The CDC's vaccine advisory committee said it will study the childhood immunization schedule in the first meeting featuring HHS Secretary RFK Jr.'s hand-selected members.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results